4.2 Review

Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics

Journal

ARTHRITIS RESEARCH & THERAPY
Volume 4, Issue -, Pages S51-S61

Publisher

BIOMED CENTRAL LTD
DOI: 10.1186/ar573

Keywords

aggrecanase; collagenase; extracellular matrix; matrix metalloproteinases; proteinase inhibitor

Categories

Funding

  1. NIH [AR40994]
  2. Wellcome Trust [057508]
  3. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Matrix metalloproteinases (MMPs) play a central role in many biological processes such as development, morphogenesis and wound healing, but their unbalanced activities are implicated in numerous disease processes such as arthritis, cancer metastasis, atherosclerosis, nephritis and fibrosis. One of the key mechanisms to control MMP activities is inhibition by endogenous inhibitors called tissue inhibitors of metalloproteinases (TIMPs). This review highlights the structures and inhibition mechanism of TIMPs, the biological activities of TIMPs, the unique properties of TIMP-3, and the altered specificity towards MMPs achieved by mutagenesis. A potential therapeutic use of TIMP variants is discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available